Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096337 · ClinicalTrials.gov registry record · NA
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
A NA study of Persistent Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- NA
- Development phase
- 484
- Enrollment target
- 20
- Study locations
NCT06096337 is a NA study of Persistent Atrial Fibrillation that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 484 participants, below the 1,228-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06096337, a NA study of Persistent Atrial Fibrillation, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 484 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.
Conditions Studied
Interventions
- DEVICE FARAPULSE™ Pulsed Field Ablation (PFA) System
- DRUG Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Study Locations (20)
Florida
- HCA Florida Mercy Hospital - Miami
- Sarasota Memorial Hospital - Sarasota
- Tallahassee Memorial Hospital - Tallahassee
- St. Joseph's Hospital - Tampa
California
- Scripps Memorial Hosptial - La Jolla
- Stanford University Medical Center - Palo Alto
- Cardiology Associates Medical Group, Inc - Ventura
Arizona
- Banner University Medical Center Phoenix - Phoenix
- Phoenix Cardiovascular Research Group - Phoenix
Georgia
- Emory University Hospital - Atlanta
- Memorial Health University Medical Center - Savannah
Massachusetts
- Brigham and Women's Hospital - Boston
- Southcoast Physicians Group - Fall River
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- Arrhythmia Research Group - Jonesboro
Illinois
- St. John's Hospital - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2028-02-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06096337
The ClinicalTrials.gov registry entry for NCT06096337 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,228-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (61% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Persistent Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which FARAPULSE™ Pulsed Field Ablation (PFA) System is the first listed.
NCT06096337 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06096337 about?
NCT06096337 is a clinical study titled "Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation". The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.
What is the current status of trial NCT06096337?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 484 participants. The study started on 2023-12-28. Estimated completion is 2028-02-04.
What conditions does trial NCT06096337 study?
This clinical trial studies the following conditions: Persistent Atrial Fibrillation.
What interventions are being tested in trial NCT06096337?
The interventions under investigation include: FARAPULSE™ Pulsed Field Ablation (PFA) System (DEVICE), Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone (DRUG).
Who is sponsoring clinical trial NCT06096337?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06096337 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Persistent Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocardial Mapping With the CoreMap EP Mapping System
RECRUITING · NA
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
ARIADNE Clinical Trial
RECRUITING · NA
-
Medtronic Terminate AF Study
RECRUITING · NA
-
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
RECRUITING · NA
-
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.